- Home
- RNXT vs BTAI Comparison
RNXT vs BTAI Comparison
Compare RNXT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | BTAI |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 35.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNXT | BTAI |
|---|---|---|
| Price | $0.92 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $23.00 |
| AVG Volume (30 Days) | 456.3K | ★ 882.0K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $267.59 | $141.28 |
| Revenue Next Year | $307.07 | $1,921.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $1.08 |
| 52 Week High | $1.45 | $8.08 |
Technical Indicators
Market Signals| Indicator | RNXT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 31.09 |
| Support Level | $0.79 | N/A |
| Resistance Level | $1.07 | $1.77 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 7.53 | 6.83 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.